Skip to main content
OpenTrials
Completed

NCT Number: NCT01054820

Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain

Although approved for minor strains, sprains and contusions, FLECTOR Patch has not been studied extensively in the setting of acute back strain. This study is being conducted as an initial step in demonstrating the benefit of FLECTOR Patch specifically for back strain. In particular, this study is expected to provide information about the amount of improvement in back strain among subjects using the FLECTOR Patch, which may then be used to inform subsequent studies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Back Strain

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants in the study must:

  • have acute, non-radicular back strain with onset up to 10 days before the first visit
  • have intact, non-damaged skin at the proposed patch application site
  • be untreated or unresponsive to conservative pain treatment regimens and/or opioids
  • have a minimum pain intensity score of four (4) or more on a scale of 1-10 (a rating of zero (0) being "no pain" and a rating of ten (10) being "pain as bad as you can imagine")
  • have a normal neurologic examination

Exclusion criteria

Participants may not be in the study if they:

  • have had surgery or other chronic pain condition within 3 months before first treatment
  • have back pain radiating below the knee at time of enrollment
  • have neuropathic pain or have been treated with gabapentin or pregabalin for neuropathy
  • are being treated for or are known to currently have kidney or liver disease
  • have certain other diseases or are using certain types of other drugs.

Treatment and study plan

FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%

Drug

One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.

Primary outcomes

  1. Mean Change From Baseline to End of Treatment (EOT) in Response to Modified Brief Pain Inventory (mBPI) Question 5: Average Pain Over the Last 24 Hours

    Time frame: Baseline, End of Treatment (last visit up to Day 15)

    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 5: Please rate your pain by marking the box beside the number that best describes your pain on the average (over the last 24 hours); rated on an 11 point Likert rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).

Secondary outcomes

  1. Number of Participants With Change From Baseline (Bsl) to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 1: Pain Other Than Everyday Kind of Pain

    Time frame: Baseline, End of Treatment (last visit up to Day 15)

    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 1: Have you had pain other than everyday kinds of pain?; response = Yes or No.

  2. Mean Change From Baseline to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 3: Pain at Its Worst in the Last 24 Hours

    Time frame: Baseline, End of Treatment (last visit up to Day 15)

    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 3: Rate your pain at its worst in the last 24 hours; rated on an 11 point Likert rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).

  3. Mean Change From Baseline to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 4: Pain at Its Least in the Last 24 Hours

    Time frame: Baseline, End of Treatment (last visit up to Day 15)

    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 4: Rate your pain at its least in the last 24 hours; rated on an 11 point Likert rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).

  4. Mean Change From Baseline to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 6: Pain Right Now

    Time frame: Baseline, End of Treatment (last visit up to Day 15)

    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 6: Rate your pain right now; rated on an 11 point Likert rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).

  5. Mean Change From Baseline to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 8: Percent Reduction in Pain From Baseline

    Time frame: Baseline, End of Treatment (last visit up to Day 15)

    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 8: Rate your percent reduction in pain from Baseline (0% = no relief to 100% = complete relief).

  6. Number of Participants Per Global Pain Relief Scores at the End of Treatment as Assessed by the Participant

    Time frame: End of Treatment (up to Day 15)

    Global pain relief as assessed by participant using a 5-point scale where 5 = complete relief, 4=a lot of improvement, 3=moderate improvement, 2=slight improvement, and 1=no change.

  7. Number of Participants Per Global Pain Relief Scores at the End of Treatment as Assessed by the Investigator

    Time frame: End of Treatment (up to Day 15)

    Participants' global pain relief as assessed by investigator using a 5-point scale where 5 = complete relief, 4=a lot of improvement, 3=moderate improvement, 2=slight improvement, and 1=no change.

  8. Mean Change From Baseline to EOT in Beck Depression Inventory® Il

    Time frame: Baseline, End of Treatment (last visit up to Day 15)

    The Beck Depression Inventory® II consisted of 21 items, each with 4 categorical responses ranging from 0 (I do not feel sad) to 3 (I am so sad or unhappy that I can't stand it) with maximum possible score of 63; increase in the number reflected an increase in severity. Total Beck Depression Inventory® II scores classified as follows: 1 to 10=normal ups and downs; 11 to 16=mild mood disturbance; 17 to 20=borderline clinical depression; 21 to 30=moderate depression; 31 to 40=severe depression; and >40=extreme depression.

  9. Number of Participants Per Patch Satisfaction Response at the End of Treatment as Assessed by Participant

    Time frame: End of Treatment (last visit up to Day 15)

    Participant satisfaction with the FLECTOR® Patch rated on a 5-point scale scored as 5=Very Satisfied, 4=Satisfied, 3=No Preference, 2=Dissatisfied, and 1=Very Dissatisfied.

  10. Number of Participants Per Patch Satisfaction Response at the End of Treatment as Assessed by the Investigator

    Time frame: End of Treatment (last visit up to Day 15)

    Investigator's assessment of participants' satisfaction with the FLECTOR® Patch rated on a 5-point scale scored as 5=Very Satisfied, 4=Satisfied, 3=No Preference, 2=Dissatisfied, and 1=Very Dissatisfied.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Multicenter, Open-Label Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Jan 22, 2010
Registry last updated
Aug 16, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.